Wall Street brokerages predict that Akebia Therapeutics Inc (NASDAQ:AKBA) will post ($0.35) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Akebia Therapeutics’ earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.41). Akebia Therapeutics posted earnings of ($0.60) per share in the same quarter last year, which would suggest a positive year over year growth rate of 41.7%. The firm is expected to issue its next earnings results on Wednesday, August 14th.
On average, analysts expect that Akebia Therapeutics will report full-year earnings of ($1.75) per share for the current year, with EPS estimates ranging from ($2.28) to ($1.41). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.63) per share, with EPS estimates ranging from ($1.66) to $0.38. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Akebia Therapeutics.
Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.02). Akebia Therapeutics had a negative return on equity of 45.06% and a negative net margin of 82.14%. The business had revenue of $72.67 million for the quarter, compared to analysts’ expectations of $83.69 million.
Institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Akebia Therapeutics by 57.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,812 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,835 shares during the period. First Quadrant L P CA acquired a new stake in shares of Akebia Therapeutics during the first quarter worth about $43,000. Great West Life Assurance Co. Can lifted its holdings in shares of Akebia Therapeutics by 80.1% during the fourth quarter. Great West Life Assurance Co. Can now owns 8,418 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 3,743 shares during the period. Caption Management LLC acquired a new stake in shares of Akebia Therapeutics during the first quarter worth about $49,000. Finally, Advisor Group Inc. lifted its holdings in shares of Akebia Therapeutics by 3,206.3% during the fourth quarter. Advisor Group Inc. now owns 9,919 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 9,619 shares during the period. 70.62% of the stock is owned by hedge funds and other institutional investors.
Shares of AKBA stock traded down $0.14 during trading hours on Thursday, reaching $4.16. 14,517 shares of the company’s stock were exchanged, compared to its average volume of 972,397. Akebia Therapeutics has a 1 year low of $4.12 and a 1 year high of $11.60. The firm has a market capitalization of $506.80 million, a price-to-earnings ratio of -1.71 and a beta of 1.51. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.15 and a current ratio of 1.71.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
Featured Article: How to use beta for portfolio diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.